560,935 Shares in Establishment Labs Holdings Inc. $ESTA Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC purchased a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 560,935 shares of the company’s stock, valued at approximately $48,134,000. Establishment Labs makes up about 2.3% of Rice Hall James & Associates LLC’s portfolio, making the stock its 5th biggest holding. Rice Hall James & Associates LLC owned 1.91% of Establishment Labs at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its stake in shares of Establishment Labs by 117.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after purchasing an additional 438,206 shares during the last quarter. Viking Global Investors LP bought a new stake in Establishment Labs during the second quarter worth $14,669,000. Soleus Capital Management L.P. bought a new stake in Establishment Labs during the second quarter worth $9,050,000. Summit Partners Public Asset Management LLC raised its position in Establishment Labs by 87.1% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company’s stock valued at $17,632,000 after buying an additional 200,255 shares during the last quarter. Finally, Nantahala Capital Management LLC lifted its stake in Establishment Labs by 11.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after acquiring an additional 197,962 shares in the last quarter. 72.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ESTA. Citigroup upgraded shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 target price for the company in a research note on Thursday. Needham & Company LLC lifted their target price on shares of Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. boosted their target price on Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. TD Cowen upped their target price on Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a research report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $100.25.

Establishment Labs Stock Performance

NASDAQ ESTA opened at $76.62 on Tuesday. The company has a market capitalization of $2.28 billion, a PE ratio of -58.49 and a beta of 1.07. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. Establishment Labs Holdings Inc. has a 52-week low of $36.53 and a 52-week high of $97.59. The company has a 50-day simple moving average of $86.83 and a 200 day simple moving average of $74.73.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The company had revenue of $67.54 million for the quarter, compared to analysts’ expectations of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The company’s revenue for the quarter was up 31.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.57) EPS. On average, research analysts predict that Establishment Labs Holdings Inc. will post -1.16 EPS for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.